HK1211030A1 - Bivalent inhibitors of iap proteins and therapeutic methods using the same iap - Google Patents
Bivalent inhibitors of iap proteins and therapeutic methods using the same iapInfo
- Publication number
- HK1211030A1 HK1211030A1 HK15111880.3A HK15111880A HK1211030A1 HK 1211030 A1 HK1211030 A1 HK 1211030A1 HK 15111880 A HK15111880 A HK 15111880A HK 1211030 A1 HK1211030 A1 HK 1211030A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- iap
- therapeutic methods
- same
- proteins
- bivalent inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261692429P | 2012-08-23 | 2012-08-23 | |
| PCT/US2013/055384 WO2014031487A1 (en) | 2012-08-23 | 2013-08-16 | Bivalent inhibitors of iap proteins and therapeutic methods using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1211030A1 true HK1211030A1 (en) | 2016-05-13 |
Family
ID=50148520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15111880.3A HK1211030A1 (en) | 2012-08-23 | 2015-12-03 | Bivalent inhibitors of iap proteins and therapeutic methods using the same iap |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8883771B2 (xx) |
| EP (1) | EP2888265B1 (xx) |
| JP (1) | JP6247298B2 (xx) |
| KR (2) | KR102237888B1 (xx) |
| CN (3) | CN104718209A (xx) |
| AU (1) | AU2013306087B2 (xx) |
| CA (1) | CA2882496C (xx) |
| ES (1) | ES2654623T3 (xx) |
| HK (1) | HK1211030A1 (xx) |
| MX (1) | MX366130B (xx) |
| RU (1) | RU2649975C2 (xx) |
| WO (1) | WO2014031487A1 (xx) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| EP3133069B1 (en) * | 2014-04-16 | 2019-09-18 | Shenzhen Yongze Pharmaceutical Co., Ltd. | Bcr-abl diploid inhibitor, preparation method therefor, and uses thereof |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JP2019514878A (ja) | 2016-04-20 | 2019-06-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｒｉｐｋ２阻害剤を含むコンジュゲート |
| CN109071525B (zh) * | 2016-05-09 | 2022-08-19 | 豪夫迈·罗氏有限公司 | 二聚化合物 |
| JP2019522633A (ja) | 2016-05-20 | 2019-08-15 | ジェネンテック， インコーポレイテッド | Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法 |
| GB201610147D0 (en) | 2016-06-10 | 2016-07-27 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB2567126A (en) * | 2017-06-23 | 2019-04-10 | Femtogenix Ltd | PBC compounds |
| CN107987083A (zh) * | 2017-11-24 | 2018-05-04 | 江苏亚盛医药开发有限公司 | 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物 |
| WO2020024932A1 (en) | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule |
| EP3831811A4 (en) * | 2018-07-31 | 2022-04-20 | Fimecs, Inc. | HETEROCYCLIC COMPOUND |
| CN113453678A (zh) | 2018-11-26 | 2021-09-28 | 德彪药业国际股份公司 | Hiv感染的联合治疗 |
| US10870663B2 (en) | 2018-11-30 | 2020-12-22 | Glaxosmithkline Intellectual Property Development Limited | Compounds useful in HIV therapy |
| BR112022005624A2 (pt) | 2019-09-25 | 2022-07-12 | Debiopharm Int Sa | Regimes de dosagem para tratamento de pacientes com carcinoma de células escamosas localmente avançado |
| TW202120081A (zh) * | 2019-11-19 | 2021-06-01 | 大陸商蘇州亞盛藥業有限公司 | 採用iap抑制劑的治療方法 |
| TW202133842A (zh) * | 2019-12-02 | 2021-09-16 | 大陸商蘇州亞盛藥業有限公司 | Iap抑制劑與parp或mek抑制劑或其他化學治療劑的組合 |
| EP4069233A4 (en) * | 2019-12-04 | 2024-03-13 | Ascentage Pharma Suzhou Co Ltd | PHARMACEUTICAL COMBINATION AND USE THEREOF |
| WO2021130270A1 (en) | 2019-12-24 | 2021-07-01 | F. Hoffmann-La Roche Ag | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
| EP4146218A1 (en) * | 2020-05-04 | 2023-03-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods for treating coronavirus infections |
| WO2022012671A1 (en) * | 2020-07-16 | 2022-01-20 | Ascentage Pharma (Suzhou) Co., Ltd. | The crystalline forms or amorphous forms of bisdiazabicyclic compounds or salts thereof |
| WO2022179490A1 (en) * | 2021-02-23 | 2022-09-01 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical compositions and preparation methods thereof |
| WO2023011488A1 (zh) | 2021-08-02 | 2023-02-09 | 苏州亚盛药业有限公司 | 一种药物组合及其用途 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2023230432A1 (en) | 2022-05-23 | 2023-11-30 | Inhibrx, Inc. | Dr5 agonist and iap antagonist combination therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040072831A1 (en) * | 2001-10-12 | 2004-04-15 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| WO2005084317A2 (en) | 2004-03-01 | 2005-09-15 | Board Of Regents, The University Of Texas System | Dimeric small molecule potentiators of apoptosis |
| CN101128425B (zh) * | 2005-02-25 | 2012-12-26 | 泰特拉洛吉克药业公司 | Iap二聚体抑制剂 |
| PT2019671E (pt) * | 2006-05-05 | 2014-12-18 | Univ Michigan | Intermediários para a preparação de miméticos de smac bivalentes |
| US8278293B2 (en) * | 2007-04-13 | 2012-10-02 | The Regents Of The University Of Michigan | Diazo bicyclic Smac mimetics and the uses thereof |
| US8815927B2 (en) * | 2009-10-23 | 2014-08-26 | The Regents Of The University Of Michigan | Bivalent diazo bicyclic Smac mimetics and the uses thereof |
-
2013
- 2013-08-16 WO PCT/US2013/055384 patent/WO2014031487A1/en active Application Filing
- 2013-08-16 CN CN201380055219.5A patent/CN104718209A/zh active Pending
- 2013-08-16 KR KR1020207013450A patent/KR102237888B1/ko active IP Right Grant
- 2013-08-16 ES ES13831176.6T patent/ES2654623T3/es active Active
- 2013-08-16 AU AU2013306087A patent/AU2013306087B2/en active Active
- 2013-08-16 CA CA2882496A patent/CA2882496C/en active Active
- 2013-08-16 EP EP13831176.6A patent/EP2888265B1/en active Active
- 2013-08-16 CN CN201811229870.0A patent/CN109575049B/zh active Active
- 2013-08-16 RU RU2015107552A patent/RU2649975C2/ru active
- 2013-08-16 MX MX2015002371A patent/MX366130B/es active IP Right Grant
- 2013-08-16 KR KR1020157006767A patent/KR102111704B1/ko active IP Right Grant
- 2013-08-16 CN CN201811229886.1A patent/CN109485662B/zh active Active
- 2013-08-16 US US13/969,030 patent/US8883771B2/en active Active
- 2013-08-16 JP JP2015528547A patent/JP6247298B2/ja active Active
-
2015
- 2015-12-03 HK HK15111880.3A patent/HK1211030A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014031487A1 (en) | 2014-02-27 |
| JP6247298B2 (ja) | 2017-12-13 |
| MX366130B (es) | 2019-06-28 |
| CN109575049A (zh) | 2019-04-05 |
| CA2882496A1 (en) | 2014-02-27 |
| AU2013306087A1 (en) | 2015-03-12 |
| CN109485662A (zh) | 2019-03-19 |
| KR20150044937A (ko) | 2015-04-27 |
| KR20200054334A (ko) | 2020-05-19 |
| MX2015002371A (es) | 2015-10-05 |
| EP2888265B1 (en) | 2017-10-11 |
| US20140057924A1 (en) | 2014-02-27 |
| US8883771B2 (en) | 2014-11-11 |
| CN104718209A (zh) | 2015-06-17 |
| AU2013306087B2 (en) | 2017-08-10 |
| KR102111704B1 (ko) | 2020-05-15 |
| RU2649975C2 (ru) | 2018-04-06 |
| RU2015107552A (ru) | 2016-10-10 |
| CN109485662B (zh) | 2021-12-21 |
| KR102237888B1 (ko) | 2021-04-07 |
| WO2014031487A8 (en) | 2014-05-30 |
| EP2888265A1 (en) | 2015-07-01 |
| CN109575049B (zh) | 2021-07-30 |
| ES2654623T3 (es) | 2018-02-14 |
| JP2015528447A (ja) | 2015-09-28 |
| CA2882496C (en) | 2020-07-14 |
| EP2888265A4 (en) | 2016-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1211030A1 (en) | Bivalent inhibitors of iap proteins and therapeutic methods using the same iap | |
| ZA201504902B (en) | Bcl-2bcl-xl inhibitors and therapeutic methods using the same | |
| ZA201501858B (en) | Anti-mcam antibodies and associated methods of use | |
| EP2970508A4 (en) | GENETICALLY MODIFIED LOADING ANTIBODIES OR ENHANCED ENHANCEMENT ENHANCEMENT TARGETING PROTEIN COMPOSITIONS AND METHODS OF USE | |
| HK1206370A1 (en) | Charged nutritive proteins and methods | |
| HK1206764A1 (en) | Nutritive proteins and methods | |
| ZA201502991B (en) | Disubstituted amino acids and methods of preparation and use thereof | |
| EP2670733A4 (en) | HDAC HEMMER AND THERAPY PROCESS THEREFOR | |
| IL286759A (en) | Therapeutic methods and preparations | |
| IL238227A0 (en) | Antibodies against c16orf54 and uses thereof | |
| EP2912178A4 (en) | SUPER AMPLIFIER AND METHOD FOR USE THEREOF | |
| IL239637A0 (en) | Human or large mammal lung bioreactor | |
| EP2833889A4 (en) | PROTEIN KINASE C HEMMER AND USES THEREOF | |
| ZA201404675B (en) | Anti-lrp5 antibodies and methods of use | |
| EP2884984A4 (en) | THERAPEUTIC COMPOSITIONS AND METHOD | |
| HK1203161A1 (en) | Peptides and methods of using same | |
| EP2938632A4 (en) | ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE | |
| HK1206762A1 (en) | Nutritive fragments and proteins with low or no phenylalanine and methods | |
| HK1209432A1 (en) | Anti-jagged antibodies and methods of use | |
| EP2909285A4 (en) | GELIFYING AGENTS AND METHODS OF USE | |
| EP2895186A4 (en) | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | |
| GB201307082D0 (en) | Pharmaceutical composition comprising 15-HETrE and methods of using the same | |
| EP2817004A4 (en) | BOUVARDIN DERIVATIVES AND THEIR THERAPEUTIC USES | |
| GB201207064D0 (en) | Pharmaceutical compositions comprising 15-hetre and methods of using the same | |
| GB201319255D0 (en) | Therapeutic compositions and methods |